MedTrace Logo

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

NCT07305246 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-26

No results posted yet for this study

Summary

This is a prospective, randomized, multi-cohort, Phase II clinical trial. The study plans to enroll 120 patients with early-stage or locally advanced, HR-positive, HER2-low breast cancer. The primary objective is to evaluate the efficacy and safety of SHR-A1811 with or without endocrine therapy compared to standard chemotherapy as neoadjuvant treatment.

Eligible subjects will be randomized centrally via an Interactive Web Response System (IWRS) using a block randomization method. Participants will be assigned in a 1:1:1 ratio to one of three treatment cohorts:

Cohort A: SHR-A1811 plus endocrine therapy (letrozole ± ovarian function suppression \[OFS\]) Cohort B: SHR-A1811 monotherapy Cohort C: Standard chemotherapy (investigator's choice of A/EC-T or TEC regimen)

Neoadjuvant Treatment:

Subjects in Cohorts A and B will receive 8 cycles of their assigned regimen. Subjects in Cohort C will receive standard chemotherapy as per the chosen protocol.

Treatment will continue until completion of the regimen, occurrence of unacceptable toxicity, withdrawal of consent, or discontinuation at the investigator's discretion.

Assessments:

Tumor imaging for efficacy evaluation will be performed every 2 cycles, with responses assessed according to RECIST v1.1 criteria. Subjects who complete neoadjuvant treatment and are deemed eligible for surgery will undergo surgical intervention within 4 weeks after treatment completion. Pathological response will be assessed from the surgical specimen. Both radiological and pathological evaluations will be based on the assessments conducted at the study site.

Adjuvant Therapy:

Following surgery, all subjects will receive standard adjuvant endocrine therapy as clinically indicated.

Conditions

Interventions

DRUG

SHR-A1811

Intravenous infusion at 4.8 mg/kg per dose, administered once every 3 weeks (Q3W). Each 3-week (21-day) period constitutes one treatment cycle, totaling 8 cycles. Administration is via intravenous infusion. The initial infusion duration is 90±10 minutes (including the flush phase). If no infusion-related reactions occur after the first administration, subsequent infusions may be shortened to approximately 30 minutes (not less than 20 minutes, including the flush phase).

DRUG

Letrozole

2.5 mg orally once daily, taken continuously.

DRUG

TAC/AC-T

Recommended standard dose

Sponsors & Collaborators

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • First Hospital of China Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2027-03-31
Completion
2027-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07305246 on ClinicalTrials.gov